New Delhi: The World Health Organisation (WHO) on Monday suspended the human trials of the anti-malaria drug hydroxychloroquine, or HCQ, to treat COVID-19 patients due to safety concerns and is being monitored by the organisation’s safety board.Also Read - Moderna Begins Next Phase of Omicron-specific Booster Trial in Adults After Pfizer-BioNTech | Read Details
“The executive group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity trial while the safety data is reviewed by the data safety monitoring board,” said WHO Director-General Tedros Adhanom Ghebreyesus during an online press briefing. Also Read - Omicron Infected Have Significant Immune Response, Can Neutralise Delta Variant: ICMR Study
The WHO director-general said a review will be conducted based on the data collected so far on harms and no-harms of HCQ within the executive group Solidarity Trial, where the drug will be re-evaluated for further tests. Also Read - Will Schools in Delhi Reopen as COVID Cases Decline? Sisodia to Discuss Matter With DDMA Today
The decision was taken after a recent study published in Lancet last week indicated that the use of the anti-malaria drug for coronavirus could increase the chances of them dying.
Notably, hydroxychloroquine has been one of the highly-touted drugs by the likes of US President Donald Trump and others who called it the “game-changer” of the viral pandemic. The U.S. President even completed his two-week course of the drug as a preventive measure after the White House staffers tested positive.